Eli Lilly (LLY) Q1 2026 Earnings Highlights: GLP-1 Momentum Fuels Strong Beat, Guidance Raised

Key Takeaways

Eli Lilly (LLY) delivered strong Q1 2026 results with total revenue of $19.8 billion, up 56% year-over-year, primarily driven by robust demand for Mounjaro and Zepbound. Non-GAAP EPS rose 156% to $8.55, significantly beating expectations. The company raised its full-year 2026 revenue guidance to $82.0–85.0 billion and advanced Foundayo approval along with multiple acquisitions. Shares rose over 6% after earnings released.

Bitget now supports LLYUSDT 20x leverage contracts! Long and short trading available — unlock even greater profit potential!

Detailed Breakdown

1. Overall Revenue and Profit Performance:
   • Quarterly revenue: $19.8 billion (+56% YoY from $12.729 billion in Q1 2025), primarily driven by 65% volume growth, partially offset by 13% lower realized prices.
   • Reported EPS: $8.26 (+170% YoY).
   • Non-GAAP EPS: $8.55 (+156% YoY), including $0.52 of acquired IPRD charges.
   • Gross margin: 81.9% (down 0.6 percentage points YoY); Non-GAAP gross margin 82.6%.
   • U.S. revenue: $12.1 billion (+43%); International revenue: $7.7 billion (+81%).
   • Reported net income: $7.396 billion (+168%).
2. Core Business (Mounjaro Zepbound) Performance:
   • Mounjaro (tirzepatide for type 2 diabetes): Global revenue $8.7 billion (+125%); U.S. $4.2 billion (+59%), International $4.4 billion (from $1.2 billion last year, driven by China NRDL inclusion but with notable price pressure).
   • Zepbound (for weight loss): U.S. revenue $4.1 billion (+79% from $2.3 billion); Global approx. $4.2 billion (+83%).
   • Key drivers: Strong demand (significant increase in prescriptions/volumes), partially offset by lower realized prices (including cash-pay reductions); Q1 one-time rebate adjustments helped mitigate some price impact.
   • Key Products overall (including Mounjaro, Zepbound, etc.): $13.4 billion (68% of total revenue); Immunology, oncology, and neuroscience Key Products up 160% YoY.
3. Other Business Segments Performance:
   • Other Key Products highlights: Ebglyss (+141%), Jaypirca (+79%), Omvoh (+115%), Kisunla and Inluriyo (new molecules, not meaningful yet).
   • RD expenses: $3.5 billion (+28%), representing 18% of revenue.
   • Marketing, selling, and administrative expenses: $2.9 billion (+19%), mainly supporting new product launches.
4. Capital Expenditure and Future Plans:
   • Pipeline highlights: FDA approval of Foundayo (orforglipron, oral GLP-1); positive Phase 3 data for Foundayo (in T2D + obesity/CV risk), Jaypirca combinations, retatrutide, etc.
   • Business development: Four acquisition agreements in the past month (Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, Ajax Therapeutics).
   • Plans: Investor community meeting on December 7, 2026; continued capacity expansion to meet GLP-1 demand.
5. Full-Year Guidance:
   • 2026 full-year revenue guidance: $82.0–85.0 billion (raised from prior $80.0–83.0 billion, up $2 billion).
   • Non-GAAP EPS guidance: $35.50–37.00 (raised from prior $33.50–35.00).
   • Expected drivers: Continued volume growth partially offsetting low-to-mid teens price headwinds; Foundayo launch to expand market.
6. Market Context and Investor Concerns:
   • Core tension: Strong demand vs. price pressure (lower realized prices for Mounjaro/Zepbound amid rising competition).
   • Market challenges: Foundayo early prescriptions soft (only 3,700 in launch week 2, vs. competitor's 18,400); capacity, reimbursement, and out-of-pocket sustainability concerns.
   • Investor reaction: Positive on strong growth momentum and pipeline, with shares rising post-earnings; however, focus remains on pricing impact to margins and new product execution risks.

Right now, Bitget's limited-time promotions are live!

I. [Weekly 0 Fees Draw - Phase 6] US Stock Contracts Trading Event Click here to join directly!

1. Lifetime 0 trading fees on US stock contracts + weekly draws with non-stop prizes
2. Participate to win free shares of hot US stocks like TSLA, NVDA, and more

II. [Earnings Season Exclusive] Copy Trading / Follow Trading on Stock Contracts 30,000 USDT Prize Pool being distributed Click here to join directly!

Disclaimer: This content is for reference only and does not constitute any investment advice.